BR112013028453A2 - composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas - Google Patents

composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas

Info

Publication number
BR112013028453A2
BR112013028453A2 BR112013028453A BR112013028453A BR112013028453A2 BR 112013028453 A2 BR112013028453 A2 BR 112013028453A2 BR 112013028453 A BR112013028453 A BR 112013028453A BR 112013028453 A BR112013028453 A BR 112013028453A BR 112013028453 A2 BR112013028453 A2 BR 112013028453A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
coating composition
core
composition suitable
dosage forms
Prior art date
Application number
BR112013028453A
Other languages
English (en)
Other versions
BR112013028453B8 (pt
BR112013028453B1 (pt
Inventor
Christian Meier
Florian Hermes
Jan Hendrik Schattka
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of BR112013028453A2 publication Critical patent/BR112013028453A2/pt
Publication of BR112013028453B1 publication Critical patent/BR112013028453B1/pt
Publication of BR112013028453B8 publication Critical patent/BR112013028453B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/12—Polymerisation in non-solvents
    • C08F2/16—Aqueous medium
    • C08F2/22—Emulsion polymerisation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/12—Esters of monohydric alcohols or phenols
    • C08F220/16—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms
    • C08F220/18—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
    • C08F265/04—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of esters
    • C08F265/06—Polymerisation of acrylate or methacrylate esters on to polymers thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2207/00—Properties characterising the ingredient of the composition
    • C08L2207/53—Core-shell polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas". a presente invenção refere-se a uma composição de revestimento adequada para o revestimento da forma de dosagem farmacêutica ou nutracêutica, que compreende um núcleo que compreende um ou mais ingredientes ativos farmacêuticos ou nutracêuticos, em que a composição de revestimento é composta por, pelo menos, 20% em peso de uma composição do polímero do núcleo/invólucro entérico derivada a partir de um processo de polimerização em emulsão, em que o núcleo da composição do polímero do núcleo/invólucro é formado por um copolímero ou um polímero reticulado, insolúvel em água e o invólucro da composição do polímero do núcleo/invólucro é formado por meio de um polímero ou copolímero aniônico.
BR112013028453A 2011-06-17 2011-06-17 Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro BR112013028453B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/060097 WO2012171576A1 (en) 2011-06-17 2011-06-17 Coating composition suitable for pharmaceutical or nutraceutical dosage forms

Publications (3)

Publication Number Publication Date
BR112013028453A2 true BR112013028453A2 (pt) 2017-01-24
BR112013028453B1 BR112013028453B1 (pt) 2021-10-19
BR112013028453B8 BR112013028453B8 (pt) 2022-07-05

Family

ID=44627081

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028453A BR112013028453B8 (pt) 2011-06-17 2011-06-17 Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro

Country Status (16)

Country Link
US (1) US9668977B2 (pt)
EP (1) EP2720681B1 (pt)
JP (1) JP5832645B2 (pt)
KR (1) KR101799625B1 (pt)
CN (1) CN103501767A (pt)
AU (1) AU2011370763A1 (pt)
BR (1) BR112013028453B8 (pt)
CA (1) CA2839494C (pt)
ES (1) ES2617402T3 (pt)
HU (1) HUE033117T2 (pt)
IL (1) IL228397A (pt)
MX (1) MX353426B (pt)
PL (1) PL2720681T3 (pt)
RU (1) RU2599023C2 (pt)
SI (1) SI2720681T1 (pt)
WO (1) WO2012171576A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775815B2 (en) * 2011-06-17 2017-10-03 Evonik Roehm Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
CN105943519A (zh) * 2016-06-22 2016-09-21 福建省微生物研究所 一种苯磺贝他斯汀掩味颗粒
KR102408027B1 (ko) * 2016-08-15 2022-06-15 에보니크 오퍼레이션즈 게엠베하 증진된 탈유화성 성능을 갖는 관능성 폴리알킬 (메트)아크릴레이트
EP3709979A1 (en) 2017-11-17 2020-09-23 Evonik Operations GmbH Process for preparing a coated hard shell capsule
JP2021524840A (ja) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
CN109232795A (zh) * 2018-09-21 2019-01-18 佛山市森昂生物科技有限公司 一种防水型高韧性包衣材料的制备方法
WO2020221522A1 (en) 2019-04-30 2020-11-05 Evonik Operations Gmbh Pellet and multi-unit pellet system (mups)
US20220241155A1 (en) * 2019-05-15 2022-08-04 Evonik Operations Gmbh Process for preparing filled hard-shell capsules with cellulose or starch-based coatings with a capsule-filling machine
IL308701A (en) 2021-05-25 2024-01-01 Evonik Operations Gmbh Hard shell capsules with modified release coating
IL308707A (en) 2021-05-25 2024-01-01 Evonik Operations Gmbh Capsule with a hard shell with prevention of the flow of gastric fluids
EP4176874A1 (en) 2021-11-09 2023-05-10 Evonik Operations GmbH Pharmaceutical or nutraceutical composition with an alcohol resistant single layer coating system
WO2023174722A1 (en) 2022-03-15 2023-09-21 Evonik Operations Gmbh Pre-functionalized hard shell capsule with accelerated drug release at ph value 5 to 5.5
WO2023214016A1 (en) 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135073C3 (de) 1971-07-14 1974-07-11 Roehm Gmbh Überzugsmittel für Arzneiformen
US4876313A (en) * 1986-08-29 1989-10-24 Rohm And Haas Company Grafted core-shell polymer compositions using polyfunctional compounds
DE9414065U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
DE9414066U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
AU771383B2 (en) * 1998-12-08 2004-03-18 Rohm And Haas Company Dirt pickup resistant coating binder and coatings
AUPQ164299A0 (en) 1999-07-14 1999-08-05 Orica Australia Pty Ltd Aqueous polymer dispersion
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
AU2003903838A0 (en) 2003-07-23 2003-08-07 Orica Australia Pty Ltd Aqueous polymer dispersion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1754766B1 (en) * 2004-05-07 2011-08-17 Asahi Kasei Chemicals Corporation Aqueous resin dispersion for adhesive and composition thereof
DE102004036437A1 (de) * 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
EP1811975A2 (en) * 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2006132471A1 (en) 2005-06-07 2006-12-14 Lg Chem, Ltd. Polymeric lubricant having multi layer structure and manufacturing method thereof
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
US20080058473A1 (en) 2006-08-31 2008-03-06 Yakov Freidzon Latex for low VOC paint having improved block resistance, open time and water-softening resistance
DE102006051020A1 (de) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
KR101454056B1 (ko) 2007-09-21 2014-10-27 에보니크 룀 게엠베하 에탄올의 영향에 대하여 내성을 가지는 비-오피오이드용 ｐｈ-의존성 조절 방출 제약 조성물
CN101801357B (zh) 2007-09-21 2013-08-07 赢创罗姆有限公司 耐受乙醇的影响的pH依赖性受控释放的药物组合物
CN102164589A (zh) 2008-09-24 2011-08-24 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
SI2341899T1 (sl) 2008-09-24 2015-04-30 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
HUE032817T2 (en) 2009-03-18 2017-11-28 Evonik Roehm Gmbh Regulated release pharmaceutical composition comprising a coating containing neutral vinyl polymers and excipients and resistant to the influence of ethanol
BRPI0924427A2 (pt) 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
CA2804929A1 (en) * 2010-07-09 2012-01-12 Lubrizol Advanced Materials, Inc. Structured acrylate copolymer thickeners

Also Published As

Publication number Publication date
JP2014517018A (ja) 2014-07-17
RU2014101228A (ru) 2015-07-27
ES2617402T3 (es) 2017-06-19
MX353426B (es) 2018-01-12
KR101799625B1 (ko) 2017-11-20
JP5832645B2 (ja) 2015-12-16
CA2839494C (en) 2018-11-06
PL2720681T3 (pl) 2017-05-31
HUE033117T2 (en) 2017-11-28
SI2720681T1 (sl) 2017-03-31
US20140079792A1 (en) 2014-03-20
BR112013028453B8 (pt) 2022-07-05
KR20140041545A (ko) 2014-04-04
IL228397A (en) 2017-07-31
EP2720681A1 (en) 2014-04-23
RU2599023C2 (ru) 2016-10-10
US9668977B2 (en) 2017-06-06
IL228397A0 (en) 2013-12-31
AU2011370763A1 (en) 2013-10-03
EP2720681B1 (en) 2016-11-23
CN103501767A (zh) 2014-01-08
CA2839494A1 (en) 2012-12-20
MX2013014143A (es) 2014-01-23
WO2012171576A1 (en) 2012-12-20
BR112013028453B1 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
BR112013028453A2 (pt) composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas
BR112013032095A2 (pt) composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas
BR112015002421A2 (pt) composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
BR112014017579A2 (pt) polímeros de silicone contendo grupos ácido sulfônico
BR112018011216A2 (pt) métodos para inibir a conversão de colina em trimetilamina (tma)
BR112013004889A2 (pt) composição de proteção de superfície sem fluoropolímero
BR112017005840A2 (pt) processos para preparar uma solução aquosa de acrilamida, reduzir concentração de ácido acrílico de uma solução aquosa de acrilamida, solução aquosa de acrilamida, homopolímero ou copolímero de acrilamida, e, solução de um homopolímero e/ou copolímero de acrilamida.
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
BR112013005195A2 (pt) forma de dosagem resistente à violação compreendendo um polímero aniônico
BR112015001371A8 (pt) Composição farmacêutica ou nutracêutica resistente ao suco gástrico com resistência contra a influência de etanol
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015008323A2 (pt) cápsulas
BR112013003847A8 (pt) métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
BR112013004416A2 (pt) agente terapêutico para enfisema pulmonar
BR112013003581A2 (pt) formulação farmacêutica ou nutracêutica gastro resistente que compreende um ou mais sais do ácido algínico
BR112015028414A2 (pt) composição farmacêutica de micela de polímero
BR112013011428A2 (pt) composição para modificar quimicamente a região interna de um fio de cabelo
BR112015005680A2 (pt) composição de revestimento aquoso, método para fornecer um revestimento, e, revestimento
BR112013022448A2 (pt) estrutura com base em polietileno
BR112015025141A2 (pt) partículas de polímero em emulsão, e, método para produção de partículas de polímero em emulsão
BR112015002258A2 (pt) injetores de combustível com face de saída do bocal não estampada e tridimensional
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
BR112013017744A2 (pt) uso de partículas de metacrilato de silicone em formulações cosméticas
BR112015023669A2 (pt) novos derivados de ciclosporina e suas utilizações

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: ROEHM GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ROEHM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: EVONIK DEGUSSA GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: EVONIK OPERATIONS GMBH (DE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2779 DE 09-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.